Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
62 hedge funds and large institutions have $14.6M invested in Genocea Biosciences, Inc. in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 10 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 61 → 62 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
84% less capital invested
Capital invested by funds: $88.7M → $14.6M (-$74.2M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $242K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$963K |
| 2 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$584K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$514K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$436K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$15.6M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.51M |
| 4 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$2.43M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.14M |
GNCA Hedge Fund Activity: Q3 2017 in Review
62 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2017, worth a combined $14.6M — down 84% from $88.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new GNCA positions and 10 closed out — a net gain of 2 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $963K. The largest seller was Fidelity Investments, cutting an estimated $16M.
- 62 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2017, up from 61 in Q2 2017.
- Funds reported $14.6M of Genocea Biosciences, Inc. stock for Q3 2017, down 84% quarter-over-quarter.
- 12 funds opened new Genocea Biosciences, Inc. positions in Q3 2017 and 10 closed out, a net change of +2 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2017 was Virtu Financial, an estimated $963K added.
- The largest Genocea Biosciences, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2017.